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The Ras-MAPK signaling pathway is highly conserved throughout evolution and is acti-
vated downstream of a wide range of receptor stimuli. Ras guanine nucleotide exchange
factors (RasGEFs) catalyze GTP loading of Ras and play a pivotal role in regulating receptor-
ligand induced Ras activity. In T cells, three families of functionally important RasGEFs are
expressed: RasGRF, RasGRP, and Son of Sevenless (SOS)-family GEFs. Early on it was rec-
ognized that Ras activation is critical for T cell development and that the RasGEFs play an
important role herein. More recent work has revealed that nuances in Ras activation appear
to significantly impactT cell development and selection.These nuances include distinct bio-
chemical patterns of analog versus digital Ras activation, differences in cellular localization
of Ras activation, and intricate interplays between the RasGEFs during distinctT cell devel-
opmental stages as revealed by various new mouse models. In many instances, the exact
nature of these nuances in Ras activation or how these may result from fine-tuning of the
RasGEFs is not understood. One large group of biomolecules critically involved in the con-
trol of RasGEFs functions are lipid second messengers. Multiple, yet distinct lipid products
are generated following T cell receptor (TCR) stimulation and bind to different domains in
the RasGRP and SOS RasGEFs to facilitate the activation of the membrane-anchored Ras
GTPases. In this review we highlight how different lipid-based elements are generated by
various enzymes downstream of theTCR and other receptors and how these dynamic and
interrelated lipid products may fine-tune Ras activation by RasGEFs in developing T cells.
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NON-ONCOGENIC Ras ACTIVATION FIRST OBSERVED IN T
LYMPHOCYTES
Ras is a membrane-bound small GTPase that plays a pivotal role in
transducing responses to diverse extracellular signals that impact
various cellular processes, prominently cell proliferation, differ-
entiation, apoptosis (1). Ras cycles between a GTP-associated
active state (Ras·GTP) and GDP-bound inactive state (Ras·GDP).
In both the Ras·GDP and Ras·GTP states the nucleotide is very
tightly bound (2–4) and for Ras activation to occur Ras guanine
nucleotide exchange factors (RasGEFs) need to loosen the grip
of Ras on the bound nucleotide, stabilizing nucleotide-free Ras
that stochastically but preferentially associates with GTP, because
GTP is present in the cell in higher concentrations than GDP
(5). Reciprocally, GTP hydrolysis is critical for inactivation from
Ras·GTP to Ras·GDP and Ras’ modest intrinsic rate of GTP
hydrolysis requires the hydrolysis-augmenting action of RasGAPs
(Ras GTPase activating proteins) (Figure 1).
The physiological importance of Ras’ GTPase activity was rec-
ognized in the late 80s through the detection and biochemical
characterization of GTPase impairing Ras mutations commonly
found in various human tumor tissues (6). Ras·GTP is a potent
signaling hub, connecting to many downstream effector mole-
cules like RAF, PI3K, and RalGDS. The best-characterized sig-
naling cascade is the Ras·GTP-RAF-MEK-ERK pathway (4, 7, 8).
In cells without mutations in Ras only a small portion of the
total amount of Ras is GTP-loaded following receptor stimuli,
which makes detection more challenging. In the early 90s Doreen
Cantrell’s group first showed Ras activation (or Ras·GTP load-
ing) in normal T lymphocytes that were stimulated with the
interleukin 2 (IL2) cytokine or a phorbol ester, agents that were
known to induce lymphocyte proliferation (9, 10). The phys-
iological significance of biochemical signals transduced by an
intact Ras-RAF-MEK-ERK pathway in lymphocytes was subse-
quently shown through transgenic expression of mutant Ras- and
MEK-alleles in thymocytes; for example, expression of dominant-
negative H-RasS17N under the control of lck promoter or catalyt-
ically inactive MEK-1 perturbs positive selection of developing
thymocytes (11, 12).
Research over the past two decades has revealed many intri-
cate ways of regulated Ras activation, not only in lymphocytes but
also in other cell types. In this review we will discuss the role of
lipid messengers in regulating the Son of Sevenless (SOS) and Ras-
GRP RasGEF families. We will focus on recent findings related to
lipid-RasGEF regulation, recent insights from novel mouse mod-
els, as well as on the ongoing debate of the cellular compartment
or location of Ras activation. For additional information on the
RasGEF family of exchange factors we refer to previous review
articles (8, 13–15).
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FIGURE 1 | Regulation of Ras family proteins. The Ras GTPases cycle
between GDP-bound inactive and GTP-bound active forms. Activation of
Ras is regulated by the balance of opposing actions of two classes of Ras
regulatory enzymes. Guanine nucleotide exchange factors (GEFs) promote
GTP-bound Ras state by enhancing exchange of GDP with GTP. GTPase
activating proteins (GAPs) enhance slow rate of intrinsic Ras GTPase
activity, promoting the inactive GDP-bound state of Ras.
THE PLAYERS; THREE FAMILIES OF Ras GUANINE
NUCLEOTIDE EXCHANGE FACTORS
The earlier-mentioned dominant-negative Ras approach estab-
lished a critical role for Ras in lymphocytes. Data from numer-
ous laboratories have meanwhile demonstrated that dominant-
negative RasS17N exerts its blocking action mainly by usurping
and blocking RasGEFs [although other features of RasS17N proba-
bly contribute to its inhibitory action (16, 17)]. Thus, the ability of
dominant-negative RasS17N to affect lymphocyte biology not only
highlights the importance of Ras but points also to a critical role
of GEFs.
If we fast-forward roughly two decades, we now know that
lymphocytes can simultaneously express three types of RasGEF
proteins (Figure 2). The overlapping expression profiles create
the impression of seemingly redundant and unnecessary complex
mechanisms to couple antigen receptor stimulation to Ras acti-
vation. However, distinct lymphocyte developmental defects in
mice deficient for unique RasGEFs argue for specialized functions
for each RasGEF (18–20). We will cover the mouse phenotypes
in more detail in subsequent paragraphs and will first focus on
the different protein domains in the three RasGEF families [also
reviewed in Ref. (5, 8)].
SON OF SEVENLESS
There are two members in SOS-family RasGEFs, SOS1 and SOS2.
Structurally, the SOS protein is composed of six domains that have
distinct functional importance: starting from the N-terminus, the
histone-like fold (HF), the Dbl homology domain (DH), the Pleck-
strin homology (PH) domain, the Ras exchange motif (REM),
the Cdc25 homology domain, and the proline-rich (PR) domain
(Figures 2 and 3). The naming of HF comes from structural resem-
blance to histone 2 dimer H2a-H2b, and HF mediates lipid inter-
action with phosphatidylinositol 4,5-bis phosphate [PI(4,5)P2,
FIGURE 2 | Structural domain organization of three families of RasGEFs
expressed inT cells. Cartoon highlighting the general protein domains in
the three families of RasGEFs: SOS, RasGRP, and RasGRF. Cdc25, Cdc25
homology domain; DH, Dbl homology domain; HF, N-terminal histone-like
fold; PH, Pleckstrin homology domain; PR, C-terminal PR domain; REM,
Ras exchange motif; EF, Ca2+-binding EF hand; C1, DAG-binding C1 domain;
CC-IQ, coiled coil – ilimaquinone domain. Protein size is drawn to
approximate scale based on SOS1, RasGRP1, and RasGRF1 (53).
hereafter PIP2] or phosphatidic acid (PA) (21). The DH domain is
a functional domain commonly found in Rho family GEFs, sug-
gesting SOS may also have Rho-specific GEF function in addition
to the more established RasGEF activity (22, 23). PH domains are
lipid/protein-interacting domains (24). The PH domain of SOS
has an auto-inhibitory function, that is regulated by interaction
with membrane lipids such as PIP2 or PA (25–29). REM-Cdc25
domains make up the RasGEF catalytic core of SOS and all other
RasGEFs. Unique to SOS, its catalytic core contains two distinct
Ras-binding sites: one for GDP/GTP exchange and the other for
allosteric regulation of SOS by Ras (30, 31). The C-terminal PR
domain is the only segment of SOS that remains to be structured
for analysis. Functionally, the PR domain contains multiple PR
motifs that can bind SH3 domain-containing proteins such as the
SH2-SH3-SH2 adapter Grb2 (32, 33), the p85 subunit of PI3kinase
(34), PLCγ1 (35–38), and Avi1/E3b1 (39). In addition, the PR
domain contains multiple documented phosphorylation sites of
ERK and probably other kinases (40–44), spiked in between the
PR stretches that are, at least in part, postulated to play a role in
feedback control of SOS activity.
RAS GUANINE NUCLEOTIDE RELEASING PROTEINS
Much less is known about the function of the domains or even the
identity of domains in the RasGRP RasGEFs. To date, there is no
RasGRP structure and we are therefore limited to make predictions
based on amino acid sequence. There are four RasGRP proteins,
RasGRP-1 through RasGRP-4, with specific expression profiles
and nuances in biochemical function. All RasGRP’s contain a cen-
tral catalytic core consisting of the catalytic REM-Cdc25 cassette.
Sequence divergency between the RasGRP and SOS REM-Cdc25
cores predicts that RasGRPs are not regulated through an allosteric
activation mechanism. Although RasGRP2 contains the REM-
Cdc25 core and early studies indicated RasGEF activity (45), it is
generally accepted that RasGRP2 functions as a GEF for the small
GTPase Rap (46). Analogously, all four proteins are predicted to
have a C1 domain positioned C-terminal of the catalytic core, but
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FIGURE 3 | Multiple membrane-derived signals determine the RasGEF
activity of SOS. (A) Model of inactive SOS. In the inactive state, SOS’s
DH-PH domains obscure the allosteric Ras-binding pocket. Without
engagement of the allosteric pocket by Ras·GTP, SOS only shows low
reactivity for Ras·GDP at the catalytic binding site. The HF docks itself to a
helical linker region (not depicted) between PH and REM domains, further
stabilizing auto-inhibited state of SOS. The protein structure of the
C-terminal proline-rich domain has not been determined to date. (B) Model
of allosteric activation of SOS. Ras·GTP binding to the allosteric site
enhances SOS exchange activity by increasing Ras-binding affinity for the
catalytic pocket, establishing a positive feedback mechanism. Other SOS
domains are omitted for simplicity. (C) Model of full activation of SOS. Full
activation of SOS requires the integration of multiple membrane-derived
signals. Grb2-mediated membrane recruitment of SOS to phosphorylated
LAT is thought to be one of the initial membrane recruitment mechanisms.
Membrane phospholipids such as PIP2 and PA interact with HF and PH
domains, and these interactions further relieve auto-inhibition state of SOS,
allowing efficient access of Ras to both the allosteric and catalytic sites.
again, RasGRP2 appears to be most divergent in that its C1 domain
does not bind diacylglycerol (DAG) (47) and RasGRP2 protein
does not translocate to the membrane when cells are stimulated
with DAG analogs (48). A third shared domain in all RasGRP pro-
teins is the pair of EF hands that occupies an interesting position
in the protein, sandwiched between the catalytic core and the C1
domain (Figures 2 and 4). EF hands typically come in pairs with
each hand binding one calcium ion (49, 50). However, not all EF
hands bind calcium. For instance, RasGRP1 with two predicted
EF hands based on the amino acid sequence can only bind one
calcium ion with one EF hand, not with both (51). Close exami-
nation of the sequence similarities and divergence in the EF hand
domains of all RasGRP proteins (not shown) tells us that there are
likely going to be substantial differences in the ways that the dif-
ferent RasGRP’s are regulated by calcium. Thus, the four RasGRP
proteins demonstrate specific biochemical regulatory mechanisms
and activities that have likely evolved over time to establish their
individual exchange functions in the specific cell types where they
are expressed. In this review we will not cover the differences
between the RasGRPs in much more detail, instead we refer you
to an excellent review by Stone (15) and one on cancer (52).
RAS GUANINE NUCLEOTIDE RELEASING FACTOR
More closely related to SOS than RasGRP are RasGRF’s; RasGRF-
1 and RasGRF-2 make up this family of proteins with multiple
domains [reviewed in Ref. (53)]. Similar to the two other RasGEF
family proteins, RasGRF proteins contain a REM-CDC25 catalytic
core domain. Uniquely, RasGRFs contain two PH domains; one
at the N-terminus (PH1) and the other PH in tandem with the
DH domain (PH2), similar to the configuration of the DH-PH
domain of SOS-family proteins (Figure 2). PH1 cooperates to pro-
mote stimulation-dependent membrane localization of RasGRF
in fibroblasts, probably through interaction with membrane lipid
(53–55). The coiled-coil (CC) domain is known to mediate pro-
tein oligomerization (56), whereas the ilimaquinone (IQ) domain
mediates calmodulin binding (57). In cooperation with the PH1
domain, CC and IQ domains notably mediate the interaction with
a MAPK p38 scaffold protein IB2/JIP2 in COS7 cells (58), which is
interesting because the DH-PH domain of RasGRF has GEF activ-
ity toward Rac (59, 60) indicating that RasGRF may efficiently link
Rac to the p38 pathway through the IB2/JIP2 scaffold protein (58).
EXPRESSION PATTERNS OF THE EIGHT RASGEF GENES
The RasGRP and RasGRF families of exchange factors have tissue-
specific expression patterns whereas SOS proteins are ubiquitously
expressed (15). For instance, RasGRP1 is expressed in dynamic
patterns in developing T cells (20, 61), in the brain (46), and in
primary keratinocytes (62). RasGRF1 and RasGRF2 are predom-
inantly expressed in the central nervous system (63). In addition,
RasGRF2, but not RasGRF1, is expressed in T cells (64). Analyses of
rasgrf2-deficient mice revealed that this RasGEF play a critical role
in the activation of NFAT target genes in T cells (64). However,
T cell development is normal in Rasgrf2−/− mice, and Rasgrf2
appears to have only limited activity toward Ras-ERK in T cells
(64). We will therefore limit ourselves to the regulation of SOS
and RasGRP here. Significantly, these two distinct types of Ras-
GEFs cooperate to establish robust yet controlled activation of Ras
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FIGURE 4 |Activation of RasGRP. (A) Depiction of RasGRP with its protein
domains. RasGRPs must be controlled to prevent spurious Ras activation
but the exact mechanism of auto-inhibition is unknown. Roles for various
domains C-terminal of the Cdc25 domain to limit membrane recruitment of
RasGRP have been proposed. (B) DAG-regulated membrane recruitment of
RasGRP. Receptor-induced generation of diacylglycerol (DAG) results in
efficient membrane recruitment on RasGRP1, RasGRP3, and RasGRP4
where these RasGEFs can encounter Ras·GDP to activate it to Ras·GTP.
RasGRP1 and RasGRP3 are known to be phosphorylated on a conserved
threonine residue at the very start of the Cdc25 domain, which enhances
their catalytic activity through an unknown mechanism. RasGRP2 does not
efficiently bind DAG and must have a different membrane-recruiting
mechanism. (C) Other regulatory mechanisms for RasGRP. Amino acid
sequence homologies predict that RasGRPs lack and allosteric Ras-binding
pocket as the one observed for SOS. RasGRP proteins contain EF hands,
structure that can often bind calcium. Calcium has been implicated in the
recruitment of RasGRP1 to the membrane but nuances appear to exist in
different cell types. It is not known if other lipid moieties such as PIP2 can
regulate the activity or residence time of RasGRP1 at the membrane.
and Ras’ RAF-MEK-ERK effector pathway (65, 66). In response
to T cell receptor (TCR) stimulation, both RasGRP1 and SOS
are recruited to the membrane where they encounter membrane-
anchored Ras and both convert Ras·GDP to Ras·GTP. Why is it
then that knockout mouse models for SOS1 and RasGRP1 show
different impairments in terms of thymocyte selection and T cell
development (20, 61, 67)?
AUTO-INHIBITION OF SOS RasGEFs
Ample structural and cellular studies indicate that catalytic activity
of SOS1 is self-limited by an intramolecular auto-inhibitory mech-
anism which involves multiple internal protein domains. Auto-
inhibition can be relieved by membrane signals from proteins and
lipid species. The physiological relevance of auto-inhibition of
SOS1 is highlighted by a clinical condition called Noonan syn-
drome (NS). NS is a relatively common autosomal developmental
abnormality and RASopathy, a disease that is caused by germ-
line mutations in molecules leading to modestly increased Ras
signaling (68, 69). NS is genetically heterogeneous: the majority
of mutations are associated with PTPN11, K-Ras, N-Ras, SOS1,
B-Raf, Raf-1, SHOC1, and CBL (69). Among eight NS-associated
genes, missense mutations in SOS1 are identified in about 10%
of NS cases (69–73). Most NS-associated SOS1 mutations are
predicted to relieve auto-inhibiting structural constraints within
SOS1, allowing increased signal output through the Ras path-
way. Indeed, several NS-associated SOS1 mutant alleles (R552G,
E108K, W729L, and E846K) have been experimentally character-
ized in vivo, showing increased Ras·GTP accumulation and ERK
activation at basal state or upon stimulation (70, 71, 74, 75). These
findings visibly illustrate that normal SOS1 function is tightly
regulated and highlight the clinical relevance of such regulation
(Figure 3A). These observed defects in fine-tuning of Ras activity
control in NS cells are also likely to impact on the patient´s immune
biology, because patients with gain-of-function mutations in Ras
proteins are at a higher risk of developing autoimmune disorders
(76–79). In the following few sections, we will review the literature
on normal SOS regulatory mechanisms and how membrane-based
signals from proteins and phospholipids influence the activation
status of SOS.
MEMBRANE RECRUITMENT OF SOS BY Grb2: INITIAL STEP
IN SOS ACTIVATION
T cell receptor stimulation leads to rapid activation of Src family
kinases and the Syk family kinase ZAP70. ZAP70 phosphorylates
the adapter LAT, a key scaffold to which various downstream signal
transducers are assembled, including molecules that are coupled
to Ras-MAPK pathway activation (80). Prior to cell stimulation,
most SOS is found in the cytoplasmic compartment, constitutively
bound to the SH3-SH2-SH3 domain-containing adapter Grb2.
Upon stimulation, SOS rapidly localizes to the plasma membrane
(PM) (32, 33, 81, 82). SOS1 membrane targeting is an essential
event for SOS-Ras activation and is mediated by binding of the SH2
domain of Grb2 (with SOS1) to phosphorylated tyrosine residues
of LAT (82). A truncated SOS1 variant incapable of Grb2 binding
is still functional as a RasGEF but can activate Ras only if targeted
elsewise to the membrane, indicating that membrane recruitment
is an essential step in ligand-dependent activation of SOS (83).
Unlike Ras, lipid modification of SOS was never been reported.
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Therefore, Grb2-mediated membrane anchorage has been viewed
as the key regulatory mechanism of SOS GEF signal output.
However, the traditional view that Grb2 association is domi-
nant or even essential for SOS1 membrane targeting has also been
challenged. Expression of C-terminally truncated SOS1 incapable
of Grb2 binding has been documented to have comparable or even
better Ras-ERK signal responses compared to full-length SOS1
(84–86). Similarly, SOS∆C, a C-terminally truncated SOS mutant
lacking residues 1050–1333 becomes recruited to the membrane
in response to serum stimulation, indicating that Grb2 is not
the only mechanism for ligand-dependent SOS1 membrane tar-
geting (29). These studies may collectively imply that Grb2 is
a redundant mechanism for stimulation-dependent SOS mem-
brane localization and subsequent SOS activation. However, little
attention is given to the physiological relevance of the protein lev-
els of the C-terminal truncated SOS1 variant examined in these
studies and time kinetics of Ras-ERK response. It is very plau-
sible that Grb2 is important and a major membrane anchorage
mechanism when physiological levels of SOS1 are available to the
activated ligand. Supporting this notion, structural studies and
recent mouse embryonic stem cell (mESC) study demonstrate that,
besides Grb2-mediated membrane recruitment, the SOS1 activity
is determined by summation of weak to moderate membrane pro-
tein and lipid interactions mediated by multiple protein domains
of SOS1 (87).
ALLOSTERIC ACTIVATION OF SOS; A POSITIVE FEEDBACK
LOOP
The SOS1-mediated nucleotide exchange rate on Ras is 500-fold
higher when Ras is membrane-bound compared to when Ras
activation is measured in solution (88), supporting a view that
ligand-dependent membrane recruitment of SOS1 not only exists
to promote the chance of substrate encounter but is also instru-
mental to enhance SOS1 enzymatic activity. One hint for the
existence and identity of additional membrane signals regulating
SOS1 came from structural studies by the Bar-Sagi and Kuriyan
groups. Unexpectedly SOS1 was found to be associated with two
discrete Ras molecules, forming a 2:1 ternary complex between
two Ras molecules and one SOS1 molecule. One Ras molecule
serves as a substrate and is bound at its catalytic pocket within the
Cdc25 domain, while the second non-substrate Ras occupies the
allosteric site in the REM domain (31). Occupation of the allosteric
site by Ras·GTP results in conformational change stabilizing SOS1
catalytic pocket and stimulates in vitro nucleotide exchange activ-
ity by∼75-fold (89, 90). In support of this notion, a SOS1 mutant
unable to bind to Ras at allosteric site (W729E) shows reduced
affinity for Ras at the catalytic site and has low in vitro activ-
ity (89). The allosteric Ras-binding pocket shows 10-fold higher
affinity for GTP-loaded Ras than Ras·GDP. This preferential affin-
ity for Ras·GTP endows SOS1 to sense the activation status of Ras
at the membrane and establishes a positive feedback regulation
(Figure 3B) (31, 91). Ectopic expression studies provided in vivo
evidence of allosteric regulation of SOS1 in COS-1 cells (89, 91) or
Jurkat cells (65, 66). Recently, allosteric mutant-SOS1 reconstitu-
tion into SOS-deficient mESC (87) and DT40 B cells (92) provided
more definitive proof of allosteric SOS1 activation regulating the
output through the Ras-ERK pathway. In addition to enhancing
catalytic activity of SOS, allosteric Ras·GTP binding could poten-
tially affect SOS residence time at the PM by providing an
additional membrane anchor for SOS1 other than Grb2 binding.
REGULATION OF SOS BY MEMBRANE LIPIDS
Current evidence argues that allosteric Ras binding to SOS1 is such
a pivotal step that SOS stays inactive unless Ras·GTP is bound at
the allosteric site (93). Then, how has SOS1 evolved to limit spon-
taneous signaling yet allow for controlled allosteric activation near
the membrane interface? In this regard, N-terminal SOS domains
play a critical role in regulating SOS1 activation in the context of
membrane proximity by sensing membrane lipids.
One membrane lipid sensing N-terminal regulatory unit is the
tandem DH and PH domain. In vitro and in vivo studies iden-
tified DH-PH domain being important for membrane-proximal
SOS regulation (29, 84, 87, 93). DH domain is commonly found
with GTP exchange factors (discussed later). In SOS, the DH
domain serves as a gatekeeper preventing promiscuous access to
the allosteric Ras-binding pocket. In its auto-inhibited state, SOS1
DH domain blocks the allosteric pocket from Ras binding, which
has a critical impact on SOS1’s catalytic pocket. Without allosteric
activation the catalytic pocket is not fully receptive to accommo-
date Ras·GDP and the helical hairpin of SOS1 is not in the correct
orientation to dislodge GDP from Ras (89, 93). PH domain is gen-
erally known for protein or lipid interactions (55). The PH domain
of SOS1 was shown to have affinity for PIP2 (25–28) or PA (29).
The auto-inhibiting DH domain can be released by electrosta-
tic interaction of membrane PIP2 or PA with positively charged
residues within the PH domain (29, 93). Therefore, lipid-DH-
PH interactions facilitate re-orientation of SOS1 at the membrane
interface, allowing allosteric Ras binding (Figure 3C). In support,
addition of cell-permeable PA to COS-1 cells is sufficient to induce
GTP loading of Ras, and charge-inversion mutations of H475E and
R479E in SOS1 abolish PA interaction and PA-induced Ras·GTP
loading response (29). Similarly, two different basic residues (K456
and R459) within the PH domain interact with PIP2 (93). The bio-
logical significance of PIP2-PH domain interaction during mESC
differentiation was elegantly demonstrated in a recent report from
Tony Pawson’s group (87).
Located upstream of DH-PH domains, the HF is an evolution-
arily conserved segment (residue 1–191) resembling dimerized
histone (21). Based on structural studies, this HF docks itself
into the helical linker region of SOS1, located between DH-PH
domains and catalytic segment (REM-Cdc25), ensuring SOS auto-
inhibition by blocking allosteric activation and by stabilizing a
closed conformation of SOS (88, 94). HF interacts with membrane
lipids such as PA and PIP2, and HF-lipid interaction reverses auto-
inhibitory docking, allowing allosteric and catalytic Ras binding
at distal and proximal Ras-binding sites (75, 88). Electrostatic
charge distribution at the phospholipid-interacting interface of
HF appears to be finely tuned by charge neutralization, e.g., the
negatively charged residue E108 is surrounded by patches of basic
residues (75). Disturbing charge balance by offsetting positive
charges leads to reduced Ras-ERK activation in COS-1 and mouse
ES cells (75, 87). Additionally, a negative charge neutralization
mutation (E108K) is found to be associated with a hyperactive
SOS1 allele of human NS (71, 75).
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There are some inconsistencies in the lipid species recog-
nized by SOS1’s N-terminal regulatory domains (29, 75, 88, 93).
This discrepancy might arise from the variability in the pres-
ence of regulatory domains or post-translational modifications of
the SOS1 proteins investigated. Perhaps more significant, mem-
brane lipids are also dynamically regulated during cell activation
processes (reviewed in Krishna and Zhong (95) in this Research
Topic and by Sauer and Cooke (96)). Perhaps, the reported dis-
crepancies regarding the role of lipid species may reflect het-
erogeneous lipid patterns in distinct cellular backgrounds and
the involvement of different lipids at different stage of SOS1
activation.
Taken together, studies in vitro and in vivo support the view
that N-terminal HF and DH-PH domains serve as membrane lipid
sensing regulatory segments. On one hand, lipid mediated regula-
tion of SOS1 leads to juxtaposition of SOS1 to substrate/effector.
On the other hand, the regulatory domains also contribute to
prevent spontaneous activation of SOS1. In this regard, it is
worth noting that the second class of human NS-associated
SOS1 mutations target N-terminal regulatory domains and often
implicate enhanced membrane recruitment of the mutant SOS
protein (73).
RasGRP AUTO-INHIBITION?
RasGRP proteins have been studied most extensively in T- and
B-lymphocytes. In these lymphocytes, RasGRP1 and RasGRP3
activate Ras in a manner that is non-redundant with SOS (18,
65, 97–101). More recently, RasGRP proteins, particularly Ras-
GRP1, have also been associated with human diseases such as
autoimmune disease and cancer.
Single nucleotide variants near RASGRP1 are associated with
susceptibility to autoimmune (Type 1) diabetes and to thyroid
autoantibodies in Graves disease (102, 103). At this point it is
not known what effect these variants in non-coding regions of
the RasGRP1 gene have, but possible mechanisms include altered
expression or RasGRP1. RASGRP1 splice variants have been doc-
umented for patients with systemic lupus erythematosus (SLE)
(104). Several of these RasGRP1 mRNA splice variants are pre-
dicted to miss portions of RasGRP1’s EF hands, which may have an
important regulatory role (see below). In addition, it also appeared
that many splice variants resulted in lower proteins expression
levels of RasGRP1 (104).
RasGRP4 was originally isolated as a Ras activator in acute
myeloid leukemia (AML) (105). RasGRP3 plays a role in human
melanoma (106) and in prostate cancer (107) that are distinct
from those of SOS. When overexpressed from transgenes, Ras-
GRP1 promotes the development of squamous cell carcinoma and
melanoma in mouse models in conjunction with skin wound-
ing or carcinogen painting of the skin (108–110). Transgenic
over-expression of RasGRP1 in developing T lymphocytes causes
thymic lymphomas in mice (111) and several unbiased mouse
model screens for leukemia genes have identified the RasGRP1
locus as a hot-spot for leukemia virus integrations driving blood
cancer (112–114). The molecular basis of these viral integrations
is that these cause leukemia through the dysregulated expression
of the target gene, typically through overexpression. Significantly,
Oki and colleagues as well as our own group have recently shown
that elevated RasGRP1 expression also occurs in T cell leukemia
patients (115, 116). For more detailed reading on RasGRP1’s
role in cancer we refer you to a different review (52). Needless
to say these studies collectively indicate that RasGRP1 requires
tight regulation. Regulation occurs most definitely at the level of
RasGRP1 expression since dysregulated expression of a wild-type
RasGRP1 form results in leukemia (116). Extrapolating from our
knowledge of SOS1, we propose that RasGRP1 also possesses an
auto-inhibited state (Figure 4A) to prevent spurious activation
and to balance the activating mechanisms of molecules like DAG,
which we will discuss next.
DIACYLGLYCEROL AS A RasGRP1 ACTIVATOR
Phorbol esters such as PMA (a synthetic DAG analog produced out
of the plant-derived compound phorbol) had long been known as
potent stimulators of Ras activation, but it was not until 1998
when Stone and colleagues cloned the RasGRP1 gene, that the
biochemical connection between DAG and Ras activation was
established (51).
In T lymphocytes that receive a TCR stimulus, PLCγ1 is
recruited to the membrane and activated so that it cleaves PIP2
into inositol-3-phosphate (IP3) and DAG. IP3 couples to the cal-
cium pathway (117) and we will come back to this in a moment.
The increase of DAG levels in the membrane results in recruit-
ment of RasGRP1 through its C1 domain to the membrane where
is can activate Ras (Figure 4B) (19, 51). There is a second, indi-
rect route from DAG to RasGRP1 and RasGRP3, which involves
PKC-mediated phosphorylation of these two RasGEFs. RasGRP1
is phosphorylated on threonine 184 (T184) in TCR-stimulated T
cells whereas RasGRP3 is phosphorylated on the analogous site,
T133, in BCR-stimulated B cells (97, 100, 118). Mutations of T184
or T133 into alanine residues results in impaired, but not absent,
stimulus-dependent Ras activation (97, 118) and incubation of
cells with PKC inhibitors blocks the phosphorylation of RasGRP1
on T184 (65, 97, 100), providing a rationale for the long estab-
lished observation that PKC inhibition inhibits the output through
the Ras-ERK pathway in lymphocytes. How the phosphorylation
of RasGRP1 and RasGRP3 enhances their RasGEF activity is not
known.
Because of DAG’s prominent role in RasGRP1 and RasGRP3
activation in T- and B-lymphocytes, generation of DAG by PLCγ
enzymes, and turnover by DAG kinases (DGKs) should be consid-
ered. In agreement with a PLCγ1-DAG-RasGRP1 signaling axis
(Figure 5), conditional PLCγ1 knockout mice and RasGRP1-
deficient mice share a similar defect in positive selection of thymo-
cytes and ERK activation (18, 119). On the other side of the cycle,
DGK’s convert DAG to PA, which is interesting because this would
dampen DAG-RasGRP signals but perhaps promote PA-SOS sig-
nals. In agreement with a critical role for DGK in dampening
RasGRP activity (as well as the activity of other proteins con-
taining DAG-binding C1 domains), deletion of DGKα and DGKγ
results in increased incidence of T cell lymphoma (120). In normal
T cells, DGK enzymes play a critical role in controlling the balance
between activation and anergy or unresponsiveness (121, 122).
For a complete review of DAG metabolism and the role of DGK
enzymes we refer to Krishna and Zhong (95) in this Research Topic.
The role of DAG in RasGRP1 regulation is obvious but may not be
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FIGURE 5 | Model of synergy between RasGRP and SOS inTCR
signaling. TCR stimulation is connected to activation of RasGRP via
tyrosine phosphorylation of the adapter molecule LAT and activation
of PLCγ1, that metabolizes PIP2 into IP3 and DAG to trigger two
second messenger pathways; Ca2+ and DAG. Activated RasGRP can
enhance the full activation of SOS by providing Ras·GTP, allosterically
activating SOS. In principle, the TCR-LAT-PLCγ1 pathway can also
indirectly facilitate SOS activation via DAG; DGK metabolizes DAG and
converts it to PA, which is a possible target for the HF and/or PH
domains in SOS.
exclusive. Non-antigen receptor triggered pathways that are typi-
cally not associated with DAG production have been implicated in
RasGRP1 membrane localization. Specifically, RasGRP1 but not
RasGRP3 signals downstream of the CXCR4 chemokine receptor
in thymocytes (123) and a heterodimer of TCR/CXCR4 has been
described to recruit the PLC enzymes essential in this pathway
(124). How different receptor systems couple to DAG and Ras-
GRP and may be able to synergistically trigger this pathway is an
interesting concept for future research.
Whereas RasGRP1 is expressed in various cell lineages (20, 46,
61, 62), it is most abundant in developing thymocytes, which
perhaps offers an explanation for the fairly specific thymocyte
developmental defect that is observed in RasGRP1-deficient ani-
mals (18). Reciprocally, RasGRP3 abundance is high in B lym-
phocytes and RasGRP3 deficient mice demonstrate B cell defects
(99), although there is a role for RasGRP1 in this lineage as well, at
least in early B cell subsets (101, 125). The developmental defects
in thymocytes lacking RasGRP1 are a consequence of severely
impaired positive selection of these cells and biochemically vis-
ible through the impaired activation of the ERK kinases (61). A
causative link between the impaired RasGRP1-Ras-ERK signal-
ing and defective positive selection has been very nicely provided
through the analyses of ERK-1 and ERK-2 doubly deficient mice
in which the thymocytes also show a positive selection defect
(126). Perhaps surprisingly, other RasGEFs, be it of the RasGRP-,
Rasgrf-, or SOS-type, do not effectively compensate for the loss of
RasGRP1 in thymocytes. The fact that there is only minimal com-
pensation for loss of RasGRP1 coming from RasGRP3 or RasGRP4
(123, 127) makes one wonder about the underlying mechanism.
Is it purely the relative abundance of RasGRP1 that bestows its
unique function in thymocytes and would expression of RasGRP3
from the RasGRP1 promoter be able to compensate for the loss
of RasGRP1? Or, are there unique biochemical properties in the
RasGRP1 protein that are lacking in other RasGEFs?
ADDITIONAL MECHANISMS OF RasGRP1 REGULATION
Only a small portion of protein flanks RasGRP1’s catalytic REM-
Cdc25 core on the N-terminal side (Figure 2). There is no pre-
dicted protein domain in this N-terminal part, but this stretch is
either only 9 or 57 amino acids long, depending on the use of an
alternative internal start codon in RasGRP1 or its most N-terminal
ATG codon (128). The C-terminus appears far more interesting.
Not only does it contain the DAG-binding C1 domain, there are
also a pair of EF hands sandwiched between the Cdc25 and C1
domains and a roughly 200-amino acid long C-terminal tail with-
out clear domains except for a leucine zipper motif (51, 129,
130). Significantly, genetic deletion of this 200-amino acid long
C-terminal tail reduces the formation of mature thymocytes in
RasGRP1d/d mice (131), thus there are critical regulatory functions
encoded on RasGRP1’s C-terminus that are relevant for thymocyte
function.
Not all EF hands bind calcium, but RasGRP1 has been reported
to bind calcium in vitro (51) and the position of the pair of EF
hands between the catalytic core and the membrane-recruitment
C1 unit is an interesting one. EF hands usually come in pairs and
are structures consisting of two α-helices connected by a loop that
contain residues such as aspartic acid, which are critical for bind-
ing and positioning of a calcium ion. The calcium-binding event
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induces protein conformational changes through the alteration
of the directional vectors of the α-helices (50). It is very possible
that calcium binding alters the structural conformation of Ras-
GRP1 and other RasGRP family members. Deducting from cell
biological assays, it appears that calcium orchestrates membrane
recruitment of RasGRP together with DAG although this may vary
from cell to cell type.
Kay and colleagues reported that in a chicken DT40 B cell line,
the first EF hand pair enables the recruitment function of a C-
terminal PT domain (PM targeting domain), which contains the
leucine zipper motif (132). Mutation of the characteristic triplet
of negatively charged aspartic acids in the first EF hand results
in impaired enrichment of this RasGRP1-EF1µ molecule to the
PM, following either BCR or G-protein coupled receptor stim-
uli. Whereas both of RasGRP1’s EF hands contain very similar
triplets of aspartic acids, mutation of these into serine in the sec-
ond EF hand does not impact the membrane recruitment of the
RasGRP1-EF2µ molecule (132). Intriguingly, the contribution of
the PT domain toward membrane recruitment appears to differ
from cell to cell type; it is substantial in BCR-stimulated B cell lines,
very modest in T cell lines, and negligible in fibroblasts (129). It
should also be noted that these studies relied on ectopic expression
of RasGRP1 that was N-terminally tagged with GFP and that the
T and B cells tested in this manner also express endogenous Ras-
GRP1. We will discuss the relevance of overexpression of molecules
in the Ras signaling pathway later. The concern of co-expressing
a tagged (and mutated) RasGRP1 together with endogenous Ras-
GRP1 is appropriate in light of the predicted leucine zipper. It is
possible that the C-terminal leucine zipper motif functions as a
RasGRP1 dimerization interface, which would make analysis of
the individual contribution of introduced- versus endogenous-
RasGRP1 molecules complex. Regardless, the Kay group studies
clearly revealed for the first time that calcium-dependent regu-
lation, while incompletely understood, plays an important role
in RasGRP1 signaling (Figure 4C). Consistent with the notion
of calcium-dependent RasGRP1 regulation, the calcium chela-
tor BAPTA-AM and a calcium channel blocker prevented the
appearance of Ras·GTP at the Golgi of activated T-cells in imag-
ing experiments (133) (see below for spatial considerations of
Ras activation). In biochemical studies, removal of all free cal-
cium by chelators had only a modest effect on TCR-driven Ras
activation (134) and RasGRP1 can activate Ras in T-cells in the
absence of free calcium (19), although it is difficult to asses the
efficiency of calcium chelation or to determine how much cellu-
lar calcium would be needed to couple to RasGRP1. In addition,
there is an enrichment of calcium ions near the negatively charged
polar headgroups of phospholipids in the PM (135), the local-
ization to which RasGRP1 is recruited via DAG. Perhaps it is the
membrane-localized calcium that is most relevant to enhance Ras-
GRP1 function. With these biochemical and cellular experiments
in mind, it is interesting to speculate on how the regulation of
various of the Lupus-associated RasGRP1 mRNA splice variants
that lack portions of the EF hands may be altered (104).
Are there additional mechanisms of RasGRP membrane
recruitment or retention that may rely on protein-protein inter-
actions or phospholipids other than DAG? RasGRP1 can interact
with a kinase dead version of PKCθ in transfected cells (100).
Similarly, RasGRP1 appears to make contacts with DGKζ (136).
It is not clear at this point if these results reflect the common
intersection point of DAG or if these are true (perhaps tran-
sient) protein–protein interactions between RasGRP1 and PKCθ
or DGKζ and what the biological implications of these may be
for lymphocytes. SKAPP-55 is a multi-domain adapter molecule
that interacts with RasGRP1 in a resting T cell line and SKAPP-
55/RasGRP1 interactions become more abundant upon TCR or
integrin stimulation (137). The immunological implication of
SKAPP55 function and its interaction with RasGRP1 are unclear,
both a positive role (138) and a negative role (137) have been
proposed. Besides a C-terminal SH3 domain, SKAP-55 contains
an N-terminal PH domain (just like SOS). It is highly specu-
lative but interesting to consider that both SOS and RasGRP1
may be regulated by phospholipids like PIP2 and PA interacting
with PH domains, but that this occurs in an indirect manner for
RasGRP1 through its interaction with SKAP-55. Lastly, Cornell
and colleagues demonstrated that RasGRP1’s PT domain har-
bors a basic/hydrophobic cluster of amino acids that is conserved
among species and that a protein-purified PT domain can bind
to phosphoinositide-containing vesicles (130). Thus, it appears
that there will be multiple mechanisms of RasGRP activation and
regulation, some perhaps surprisingly similar as for SOS RasGEFs.
BIOCHEMICAL SYNERGY BETWEEN SOS1 AND RasGRP1
When SOS and RasGRP’s are co-expressed in a T cell, TCR stim-
ulation can take two routes to Ras-ERK activation; one through
RasGRP and the other through SOS (Figure 5). However, genetic
studies in cell lines and mice indicate that RasGRP plays a more
dominant role in antigen receptor-stimulated Ras-ERK activation
(18, 61, 66, 67, 92, 139). A recent study also reports that SOS1/2
maybe inhibitory for TCR-induced ERK activation in human
peripheral T cells (140), although this finding is inconsistent with
several other studies showing a positive contribution of SOS in
antigen receptor-stimulated ERK activation, both in lymphocyte
cell lines and primary mouse and human lymphocytes (20, 65–67,
92). Reduction of SOS expression leads to moderate but consistent
ERK activation impairment in human peripheral T cells, mouse
DP thymocytes, and DT40 B cell line (20, 66, 67, 92, 139). Fur-
thermore, the ERK activation defect in SOS1−2− DT40 cells is
most noticeable at low and physiological levels of antigen receptor
stimulation, indicating that ranges of stimuli across multiple time
points are required to conclusively analyze ERK activation defects
(66, 92, 139).
Interestingly, flow cytometry-based examination of ERK acti-
vation for single cells within a population revealed that not only
the quantity but also quality of phosphorylated ERK (pERK) out-
put differs depending on RasGEFs connecting stimulated antigen
receptor to Ras (66). In the DT40 model B-cell system, the pERK
pattern in BCR-stimulated wild-type DT40 cells (co-expressing
RasGRP1/3 and SOS1/2) demonstrates a highly thresholded and
bimodal/digital pERK pattern. RasGRP1/3 double-deficiency in
DT40 cells results in poor pERK response consistent with near
abolished ERK activation in RasGRP1-deficient mouse lympho-
cytes, indicating that RasGRP play a dominant role in ERK
regulation (66). In the absence of SOS1/2, RasGRP1/3 can still
activate ERK downstream of BCR, albeit at reduced level. More
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significantly, these flow-based assays show that RasGRP1/3-driven
ERK activation gradually increases over time and displays ana-
log/unimodal pERK patterns, but does not yield a bimodal pattern
(Figure 6).
Multiple models at different levels of Ras/MAPK signal trans-
duction explain the shaping of digital/bimodal ERK activation,
such as Ras nano-clusters (141), dual negative feedback control
by SHP-1 (142) or scaffold-mediated signal quality change (143),
and subcellular location of cascade activity (144). But, none of
pre-existing models explain the change in ERK activation pat-
tern depending on the RasGEFs availability. Based on computer
modeling analysis, we hypothesized that the optimal Ras-ERK
response observed in wild-type cells co-expressing SOS and Ras-
GRP involved allosteric activation of SOS primed by Ras·GTP
produced by RasGRP. To test this hypothesis, we uncoupled the
potential positive feedback loop between two RasGEFs by intro-
ducing W729E mutation that prevents Ras·GTP binding at the
SOS1 allosteric pocket (66, 89, 92). Whereas RasGRP1 is compara-
bly activated (measured by T184 phosphorylation), BCR-induced
Ras-ERK response in cells expressing W729E mutant-SOS1 resem-
bles that of SOS1/2-deficient cells [unpublished data (92)]. Which
RasGEF generates an initial flux of Ras·GTP priming full activa-
tion of SOS? Theoretically, allosteric activating Ras·GTP can come
from self (SOS) or from RasGRP. Indeed, HeLa cervix carcinoma
cells that do not express RasGRP1 (Roose lab, data not shown) are
able to engage the SOS-Ras·GTP-SOS loop in response to EGFR
stimulation (91). However, both lymphocyte cell lines and primary
lymphocytes lacking RasGRP poorly respond in terms of Ras-ERK
activation, indicating that RasGRP plays an essential role in ERK
activation by signaling to Ras-ERK but also to Ras-SOS, via an
early surge of Ras·GTP allosterically activating SOS (18, 61, 65–67,
92, 139).
NOVEL INSIGHTS AND PUZZLES FOR THYMOCYTE
SELECTION SIGNALS FROMMOUSE MODELS DEFICIENT FOR
RasGEFs
In the cellular context where two RasGEFs co-exist, biochemical
activation of RasGRP appears temporally ahead of activation of
SOS (Roose lab, data not shown). Moreover, whereas SOS requires
allosteric activation by Ras·GTP and therefore in a sense relies
on RasGRP1 (65), the reverse relationship does not exist: Ras-
GRP1 does not appear to require SOS. These relationships between
RasGRP/SOS lead to the hypothesis that the differential fate of
thymocytes undergoing selection might be determined by how
two RasGEFs are differentially activated upon TCR stimulation
(145). This hypothesis was also founded by the observation that
positively selected DP thymocytes demonstrate graded (or analog)
ERK activation (146, 147). In this model, weak TCR stimulation of
positively selected thymocytes sub-optimally phosphorylates LAT,
enough to activate PLCγ1-DAG-RasGRP1 pathway and analog
ERK signals but without coupling SOS1 membrane recruitment
and digital ERK signaling (Figure 6). Genetic support for this
FIGURE 6 | Differential activation of RasGEF determines the quantity and
quality of Ras-ERK output. Left: full activation of the ERK response requires
activation of both RasGRP and SOS and can lead to bimodal (digital) ERK
activation patterns. In this mode of signaling, RasGRP activation temporally
precedes activation of SOS and provides initial Ras·GTP that primes full
activation of SOS. Middle: in the absence of SOS, there is substantial
Ras-ERK activation mediated by RasGRP alone, but the ERK activation
patterns are analog and therefore differs both quantitatively and qualitatively
from ERK signal generated by two RasGEFs in synergy. Right: in
lymphocytes, RasGRP plays a dominant role in connecting TCR-Ras-ERK
pathway. SOS alone has difficulty to prime its own allosteric activation, which
results in a high threshold for Ras-ERK activation.
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model comes from the observation that RasGRP1 is essential for
positive selection but is not required for negative selection (61, 67).
On the other hand, strong TCR stimulation during negative selec-
tion induces extensive LAT phosphorylation, enough to recruit
and activate both RasGRP1 and SOS1, and enable allosteric activa-
tion of SOS, which generates strong ERK activation characteristic
of negatively selected DP thymocytes (66, 147). Whereas this is a
plausible model it does not address the question if digital SOS-ERK
signals are negative selection cues for thymocytes. In fact, genetic
deletion of ERK-1 and ERK-2 does not impair negative selection of
DP thymocytes at all (148), perhaps arguing that the characteris-
tic ERK activation profiles of thymocytes under negative selection
conditions is only a byproduct of a different signal that causes the
true negative selection (we will discuss this later). Furthermore,
recent studies of a conditional SOS1 knockout mouse model from
Samelson and colleagues provided yet another puzzling insight
into the different roles of RasGEFs during T cell development (20,
67), which we will discuss next.
Conditional genetic deletion of SOS1 in thymocytes,
SOS1(T)−/− revealed that SOS1 is dispensable for negative selec-
tion, disfavoring the previously mentioned differential-RasGEF-
usage model for thymocyte fate decision [reviewed in Ref. (149)].
Instead, SOS1 expression is required for DN stage thymocytes
undergoing DN to DP transition. SOS2 deficiency alone does
not significantly affect either positive or negative selection (67).
The developmental block in SOS1(T)−/− thymocytes is accounted
for by impaired proliferative expansion of DN to DP thymocytes
(20). The early developmental defect in SOS1(T)−/− thymocytes
can be explained by developmental stage-specific expression pro-
file of different RasGEFs: protein level of SOS1 and RasGRP1
dynamically changes as thymocytes develop. SOS1 protein level
is highest in DN thymocytes, while DP thymocytes only express
20% of the SOS1 levels seen in DN thymocytes. RasGRP1 pro-
tein level follows the opposite trend: little RasGRP1 is expressed in
DN, RasGRP1 is most abundant in DP thymocytes (20, 61). Most
puzzling is the finding that combined deletion of RasGRP1/SOS1
impairs negative selection (67). What would be the signaling com-
ponents regulated by two RasGEFs for negative selection? It is
unlikely to be Ras-ERK since negative selection is not affected in
H-RasS17N transgenic nor in Erk1−Erk2− doubly deficient thy-
mocytes, indicating that Ras-ERK activation is dispensable for
negative selection (12, 148).
One explanation could be that rather than mediating TCR-
sparked responses, both GEFs provide a permissive type of input
by sustaining steady-state, basal Ras and Ras-effector levels, as doc-
umented in other systems (150, 151). Another explanation may be
provided by other functions of RasGEFs in addition to activation
of the canonical Ras-ERK pathway. Pharmacological inhibition of
the p38 MAPK impairs negative selection in fetal thymic organ
culture system (152). Additionally, both Grb2 haploinsufficiency
as well as complete Grb2 deletion is concomitant with reduced p38
activation and impaired negative selection (153, 154). We recently
uncovered an unanticipated link between SOS and p38 (92). Sig-
nificantly, SOS1 plays a critical role to connect TCR triggering
to p38 activation. By contrast, RasGRP1 plays only a very minor
regulatory role in TCR-induced p38 activation in human periph-
eral T cells and Jurkat cell line and p38 activation is unaffected in
thymocytes deficient of RasGRP1 (92). Surprisingly, SOS1’s role
in p38 activation is independent of allosteric activation of SOS or
even of any enzymatic activity in SOS1, arguing that this is indeed a
non-canonical SOS pathway [discussed in more detail later; (92)].
SPATIAL CONTROL OF Ras ACTIVATION: A ROLE FOR LIPID
MESSENGERS AND GEFs IN COMPARTMENTALIZED Ras
SIGNALING?
Traditionally, Ras activation in leukocytes and other cell types
has been intuitively assumed to proceed at the PM based on the
notion that Ras activation is bound to happen in close prox-
imity to growth factor or antigen receptor systems that do, in
their majority, operate at the cell surface. Early immunocyto-
chemical studies confirmed the predominant presence of Ras at
the PM (155–162), lending support to the view that Ras acti-
vation proceeds at the PM. However, a diffuse staining of the
cytoplasm was apparent in some reports (155, 161, 163), sug-
gesting early on that meaningful amounts of Ras proteins might
also be present and signal from internal membranes (endomem-
branes). The concept that Ras proteins do associate with subcel-
lular membranes was cemented in a series of studies from the
1980s documenting that Ras proteins are subject to a complex
series of post-translational modifications that gradually increase
their hydrophobicity and effectively govern the association of Ras
with cellular membranes [for a review, see (13, 164, 165)]. Recent
imaging studies have added a spatial and temporal dimension to
this view by showing, firstly, that the stepwise post-translational
processing of nascent Ras proteins proceeds at endomembranes en
route to the PM (163), and second, by disclosing dynamic cycling
of the two palmitoylated Ras proteins H-Ras and N-Ras between
PM and endomembranes in dependency of their palmitoyla-
tion status (166–169). According to this latter “acylation cycle”
model, palmitoylation at the Golgi apparatus “traps” H-Ras and
N-Ras proteins at endomembranes, tagging them for exocytotic
transport and accumulation at the PM. Upon depalmitoylation
by the recently characterized acyl protein thioesterase 1 (APT1)
(167, 170) and possibly other as yet unidentified depalmitoylat-
ing activities, Ras proteins loose their tight and inert binding to
the PM, leading to a fast inter-membrane exchange of depalmi-
toylated Ras and, in consequence, to the tendency to distribute
equally to all cellular membrane compartments. One round of
the cycle is completed by the renewed palmitoylation of Ras at
the Golgi apparatus, a reaction that essentially provides a vec-
torial component ensuring the predominant localization of Ras
at the PM. In contrast to the dynamic palmitoylation-dependent
cycling of H-Ras and N-Ras, the non-palmitoylated K-Ras protein
is assumed to reside and function largely at the PM, although alter-
native modes for K-Ras internalization have also been described
(171, 172). Knowing this, the intriguing question is whether
compartmentalization of Ras activity represents a means of sig-
nal diversification in antigen receptor signaling and whether or
not second messenger lipids coordinate spatial aspects of Ras
activation.
IMAGING ACTIVE Ras·GTP IN T-CELLS
In 2003, Mark Philips and coworkers presented the first of a series
of studies that reported for the first time a view of Ras activation
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in real-time in lymphocytes challenged via the T-cell receptor
(133, 173, 174). Ras·GTP visualization was accomplished using
a genetically encoded, fluorescent reporter probe composed of
EGFP and the Ras-binding domain (RBD) of the Ras-effector
c-Raf. EGFP-RBD features several orders of magnitude higher
affinity for Ras·GTP versus Ras·GDP causing it to redistribute
and illuminate subcellular sites of Ras·GTP accumulation (162,
175, 176). However, levels of endogenous Ras·GTP are too low to
be visualized by EGFP-RBD and researchers have been forced to
overexpress Ras. Use of EGFP-RBD to image activation of over-
expressed Ras in Jurkat T-cells challenged by clustering the CD3ε
chain of the TCR alone or in combination with co-stimulatory
triggers yielded an unexpected picture: a bimodal pattern of Ras
activation consisting of K-Ras activation at the PM followed or
paralleled by a more sustained accumulation of N-Ras·GTP at
the Golgi apparatus (173). Strikingly, N-Ras became GTP-loaded
only at the Golgi despite the fact that it was present in large
amounts at the PM, where the same TCR stimulation induced
robust GTP loading of K-Ras (174). While the precise mecha-
nisms enabling the TCR to discriminate among Ras isoforms and
subcellular platforms of activation are not fully clear, a number
of factors involved in spatial control of Ras activation have been
characterized. Pharmacological experiments and use of geneti-
cally engineered Jurkat lines provided evidence that the delayed
Golgi activation of N-Ras occurred by means of a PLCγ1/RasGRP1
pathway acting specifically on Golgi-resident N-Ras (133, 173),
whereas SOS and RasGRP1 acted in concert to load K-Ras with
GTP at the PM. Intriguingly, the segregation of the Ras·GTP
reporter probe to PM versus endomembranes depended on a
number of stimulation parameters: first, the strength of TCR stim-
ulation, with low-grade stimulation (achieved by applying CD3
and CD28 cross-linking antibodies at a final concentration of
1µg/ml) causing the accumulation of the Ras·GTP reporter only
at the Golgi apparatus, whilst high-grade stimulation (5µg/ml)
lead to the described b dual activation pattern (133, 173). This
distinct activation pattern was attributed to the ability of low-
grade TCR signals to engage the Golgi-specific PLCγ1/RasGRP1
pathway but not other pathways targeting K-Ras at the PM (173).
Arguing against this scenario, other investigators have reported
K-Ras activation in response to anti CD3ε Abs administered at
concentrations as low as 0.15µg/ml (19, 177), suggesting that
low-grade TCR signals cannot discriminate between PM and
endomembrane Ras-pools or between K-Ras and N-Ras isoforms.
Interestingly, non-leukocyte cell lines like COS, MDCK, or HeLa,
which do not express RasGRP1 (150, 168) (Roose, unpublished)
exhibit the same segregation of EGFP-RBD to the PM and Golgi
in response to growth factor stimulation (133, 169, 178, 179), evi-
dencing that mechanisms of endomembrane Ras activation other
than the RasGRP pathway do exist. Data from Bastiaens lab illus-
trate that (overexpressed) Ras·GTP generated at the PM of MDCK
cells relocates to endomembranes following its depalmitoylation
at the cell surface in the context of the acylation cycle (169, 179).
This mode of endomembrane Ras activation may well operate
also in T lymphocytes, but this would imply that endomem-
brane Ras activation should be preceded by a first “wave” of
N-Ras activation at the PM, which was not reported in those
studies (173, 174). In conclusion, the individual contribution
of the two known modes of endomembrane Ras activation in
TCR signaling in T lymphocytes still needs to be evaluated in
detail.
THE ROLE OF CO-STIMULATION
Another parameter that can affect the spatial segregation of
Ras·GTP is the nature of the co-stimulus provided along with
the CD3-cross-linking Ab. For example, CD28 co-stimulation
enhances DAG production in T-cells (121, 180) and this in turn
is expected to enhance Ras activation via RasGRP1. CD28 co-
stimulation is thus intuitively expected to affect the magnitude
and possibly also the location of Ras·GTP formation. Somewhat
unexpectedly, therefore, this turned out not to be the case, since
co-stimulation with soluble CD28 antibodies does not ostensi-
bly affect Ras·GTP levels and/or Ras·GTP localization (174, 177).
Perhaps CD3/CD28 co-stimulation experiments need to be re-
evaluated using immobilized rather than soluble Abs for receptor
crosslinking (181). Co-stimulation via the lymphocyte function-
associated antigen-1 (LFA-1), on the other hand, was reported to
stimulate activation of Ras at the PM (174). Interestingly, LFA-1
facilitated Ras·GTP formation by stimulating the generation of
DAG at the PM via the sequential action of PLD2 and Phos-
phatidic acid phosphate (PAP), a pathway that had before been
linked to DAG/PA metabolism at the Golgi (182). In agreement
with an important role of LFA-1 signals for Ras·GTP formation,
co-stimulation via LFA-1 reportedly enhanced Ras·GTP accumu-
lation in response to TCR-clustering (174). In opposition to that
scenario, others have not observed an effect of LFA-1 on Ras·GTP
levels in T-cells (177). Along the same vein, co-stimulating T-cells
via SLAM, a measure that also leads to an enhanced produc-
tion of DAG in T cells (180) did not further stimulate Ras·GTP
production, further indicating that an elevation of DAG levels
in response to particular TCR/co-receptor stimulations does not
always automatically translate in elevated Ras·GTP levels.
ENDOGENOUS VERSUS OVEREXPRESSED Ras AND OTHER
EXPERIMENTAL CONSIDERATIONS
The pioneering imaging studies described above have changed
the way we think about Ras activation, away from the traditional,
rather unilateral view of “static” Ras proteins acting at the PM
to the more dynamic picture that has now emerged and has
been delineated in the previous sections. It is, however, impor-
tant to recall that the experimental approaches that have led to
this new conception feature a number of caveats and limitations
that should be borne in mind. One limitation is that stimulation
with cross-linking antibodies toward the CD3ε chain and various
co-receptors, as used for reasons of simplicity in most studies, may
not reliably reflect the physiological setting of a T-cell challenged
by an antigen-loaded APC. Secondly, overexpression of Ras pro-
teins, as applied in most imaging experiments, is an issue worth
considering.
Since Ras activation and trafficking are finely regulated
processes it is arduous to judge whether or not images obtained
from cells overexpressing Ras proteins do always truly reflect
the behavior of endogenous Ras. Evidence arguing that this may
indeed be an important fact to bear in mind comes from studies
reporting on the subcellular localization of endogenous Ras·GTP
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in live T cells (177, 183). Visualization of endogenous levels of
Ras·GTP in T cells was achieved using refined fluorescent biosen-
sors for Ras·GTP that consisted of three concatenated RBD mod-
ules, yielding increased avidity toward Ras·GTP (183), and three
EGFP proteins, that conferred threefold higher fluorescence inten-
sity to the probes (177). These probes redistributed only to the
PM of PMA or TCR-stimulated Jurkat cells and to the immuno-
logical synapse of primary T lymphocytes conjugated to APCs
(177, 183), but the probes did not illuminate the Golgi or other
endomembranes, in contrast to what was observed in T cells over-
expressing H-Ras or N-Ras (133, 174). This remarkable variance
in experimental outcome can be interpreted in two ways: first,
the trivalent EGFP× 3-RBD× 3 reporter probes do illuminate
endogenous Ras·GTP formed at the PM but they are not sensi-
tive enough to visualize Ras·GTP at the Golgi. Since the signals
obtained for endogenous Ras·GTP at the PM using the EGFP× 3-
RBD× 3 biosensors are clear and well visible, this interpretation
would imply that Ras·GTP levels at the Golgi are markedly lower
than those at the PM. The alternative explanation is that accumu-
lation of N-Ras·GTP at the Golgi results from perturbances in Ras
trafficking, processing, or activation processes as a consequence of
Ras overexpression. For example, the reported relocation of GAPs
to the cell surface at later stages of TCR signaling for the shutdown
of PM Ras signaling (133, 184) could cause a drop in GAP activity
at endomembranes that could facilitate increased Ras·GTP load-
ing at the Golgi in a background of Ras overexpression. Also, a
sheer increase in the flux of N-Ras through the acylation cycle in
Ras overexpressing T-cells is expected to lead to the redistribution
of more N-Ras·GTP from the PM to endomembranes. In sum, it is
currently difficult to judge whether the observed accumulation of
overexpressed N-Ras·GTP at the Golgi is a physiological response
of T-cells to antigen stimulation or rather reflects an effect that is
only seen with anomalously high levels of Ras.
COMPARTMENTALIZATION OF DAG-RasGRP1 SIGNALS
Given that Ras activation downstream of the activated TCR is
largely driven by the concerted action of SOS and RasGRP1 GEFs,
can knowledge about the segregation of GEFs and the lipid sec-
ond messengers that regulates GEF action help us understand
the spatial control of Ras activation? The subcellular distribution
and TCR-dependent, spatially localized formation of DAG, as the
most prominent lipid second messenger involved in the regula-
tion of Ras activity, have been investigated in quite some detail.
In addition to its presence at the PM, DAG is present in meaning-
ful amounts at various other subcellular sites including the Golgi
apparatus and the nuclear membrane (185, 186). It appears that
the sources for these distinct pools of DAG are different. For exam-
ple, DAG at the Golgi arises largely from Sphingosine metabolism
and to some extent also from the sequential action of PLD and
PAP on phospholipids (182, 187). PM-located and nuclear DAG
is mostly replenished by de novo synthesis but is also generated to
a variable extent by the action of Phospholipases of various kinds
on precursor phospholipids (for comprehensive reviews on DAG
metabolism see (187, 188) and in this review issue). Although lym-
phocytes reportedly have a pool of nuclear DAG, too (186), most
attention has been devoted to the PM and Golgi-populations of
DAG, since these are, arguably, the two major platforms of TCR
signaling. While some subcellular sites, prominently the Golgi
apparatus, are rich in steady-state levels of DAG (182), it is gen-
erally assumed that DAG-dependent signaling downstream of the
TCR involves the de novo generation and spatially restricted accu-
mulation of DAG in response to antigen stimulation. Since DAG
can directly recruit the Ras activator RasGRP1 it appears reason-
able to predict, that domains of DAG formation in response to TCR
stimulation should coincide with sites of Ras·GTP accumulation.
Where does TCR-sparked DAG production occur and where
within the antigen-stimulated T-cell does DAG accumulate? Sev-
eral laboratories have imaged DAG in live T-cells using fluorescent
reporter probes derived from DAG-binding domains including C1
domains from RasGRP1, PKCθ, or PKD (189–192). Interestingly,
C1 domains from RasGRP1 or PKCθ illuminated endomembranes
in unstimulated T-cells, suggesting that resting levels of DAG in T-
cells are primarily found in that compartment. Upon conjugation
with APCs, the same reporter probes relocalized to the IS (190,
191), illustrating that DAG accumulates at the IS. The accumula-
tion of active PLCγ1 (assessed by phosphorylation on Y783) to PM
and IS in response to TCR cross-linking or conjugation with APCs
(193) is also in line with this view. Consistent with the notion that
TCR-activation induces DAG formation/accumulation at the PM,
the full-length versions of the DAG-effector proteins PKD and
chimaerins accumulate at the PM or IS of TCR-challenged T-cells
(194). DGKα and DGKζ, two enzymes that metabolize DAG by
converting it to PA, also accumulate at the PM of T-lymphocytes
conjugated to antigen-loaded APCs (192, 195), a step proposed
to be critical for the spatial confinement of DAG to the IS (196).
In the case of RasGRP1, some studies reported exclusive redis-
tribution of RasGRP1 to the PM or IS of T-cells challenged via
the TCR (122, 177, 194, 197–200) while others documented TCR-
activation dependent accumulation of RasGRP1 at PM and Golgi
(133, 147, 174). Importantly, while these considerations may cause
the impression that DAG alone determines the subcellular distrib-
ution of many of its effector proteins, DAG is likely to be only one
of various factors that coincidentally determine the spatial distri-
bution of RasGRP1 and other DAG-target proteins. For example,
the DAG-effector PKD features a transient and short-lived recruit-
ment to the IS despite the much more prolonged presence of DAG
at the IS (191).
COMPARTMENTALIZATION OF LIPID-SOS SIGNALS?
Recently, the lipid product of PLD, PA, has been reported to recruit
SOS via its PH domain, thus providing yet a new link for a lipid
messenger and Ras activation. Since PA is found both at the PM
and endomembranes (174, 182), mechanisms for the oriented
and regulated recruitment of SOS to subcellular membranes must
exist. This involves probably the concerted action of PA with other
upstream inputs such as PIP2, Ras-binding, and Grb2 binding, as
described extensively above (see sections on SOS regulation).
Another important second messenger lipid with relevance
to SOS-driven Ras activation is the PI3K reaction product
phosphatidylinositol-3,4,5 trisphosphate (PIP3) (201, 202). The
subcellular distribution of PIP3 in lymphocytes has been visual-
ized using fluorescent reporter proteins based on the PH-domain
of Akt (203–205). These studies reported that PIP3 was produced
and accumulated at the PM, but in contrast to DAG, PIP3 was
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not restricted to the IS but expanded also to regions outside the IS
(203). Indeed, a sustained accumulation of PIP3 was even observed
at the antisynapse or uropod of the T-cell (204). Remarkably,
other upstream modulators or known activators of Ras like ZAP70
and ezrin, respectively, also accumulate at the antipodal pole of
conjugated T-cells (206–208). Intriguingly, ezrin is an important
co-factor in Sos activation in some systems (207), which raises
the intriguing possibility that concerted Sos-dependent Ras acti-
vation by means of ezrin and PIP3 and subsequent Ras-signaling
(to PI3K?) may proceed at the T-cell uropod at later stages of
T-cell-APC conjugation.
The subcellular distribution of PIP3 in the course of T-cell stim-
ulation is consistent and certainly suggestive of a role of PI3K in the
control of Ras activation and/or signal propagation. However, the
precise role played by PI3K and its lipid products in Ras activation
is an intensively debated, and as yet not settled issue. PI3Ks [refers
collectivelly to the four members of the class I family of PI3Ks
(209)] were originally described and characterized as effector pro-
teins of Ras, and a large body of experimental evidence [including
the recent analysis of transgenic animals expressing PI3K vari-
ants that cannot be activated by Ras·GTP (210, 211)] has firmly
established the notion that PI3Ks do function downstream of Ras
[reviewed in Ref. (212)]. On the other hand, a number of studies
has also documented a role for PI3K upstream of Ras (201, 202,
213), indicating that PI3K lipid products could fulfill dual roles as
second messengers in the propagation of Ras-sparked signals and
as modulators in the (feedback?) control of Ras activation.
How could PI3K lipid products regulate Ras activation in
lymphocytes? PIP3 interacts physically with the Ras-GAP species
GAP1(m) (214) and biochemical evidence for a regulation of Ras-
GAP activities by PIP3 in leukocytes does exist (202). Beyond this
largely unexplored connection with GAP proteins, PIP3 interacts
with and recruits members of the Tec family of protein kinases,
prominently Bruton’s tyrosine kinase, Btk, in B cells and Itk in
T-cells (215), via an amino-terminal PH domain (216–218). Tec
kinases, in turn, can affect Ras activation in two ways: first, Tec
kinases are critically involved in antigen receptor-induced PLCγ
activation (219, 220), and defective Tec activation in response to
antigen receptor stimulation leads to a number of defects in path-
ways dependent on DAG/IP3, including PKC and ERK activation
(221, 222). The latter finding suggests that Ras activation should
also be affected, although this has, to our knowledge, not been
directly assessed. Secondly, defects in Tec kinase function cause a
decrease in PA levels (223), which could in turn result in dimin-
ished Ras·GTP loading via SOS (29). In this regard, it is probably
important to consider PIP3 in a broader context in conjunction
with the fate of its precursor lipid PIP2. Beyond serving as a sub-
strate for PI3Ks, PIP2 plays a critical function as the substrate of
PLCγ enzymes and it is well established that the agonist-evoked
activation of PI3K and PLCγ signaling can lead to a marked, acute
and probably spatially restricted drop of PIP2 levels in leukocytes
(224, 225). Since PIP2 can modulate Ras activation via the direct,
PH-domain dependent interaction with SOS, the concerted and
locally confined regulation of the PIP2/PIP3 ratio is predicted to
have a large impact on the activation status of Ras. From a technical
point of view, one important challenge for the years to come will
be to address this aspect of Ras activation by visualizing PIP2 and
PIP3 simultaneously with Ras·GTP in life cells, an approach that
should ideally be expanded to other second messengers involved
in the control of RasGEFs.
A PHYSIOLOGICAL ROLE FOR COMPARTMENTALIZED Ras
SIGNALING?
Is the segregation of Ras signaling to endomembranes and possibly
other subcellular sites an inherent and fundamental component of
TCR signaling that provides an additional level of signal diversifi-
cation? Evidence for a possible physiological role of compartmen-
talized Ras signaling in T-cell biology comes from provocative data
reported by Ed Palmer’s lab arguing that Ras localization and sig-
naling from PM versus endomembranes could be a major fate
determinant during thymic T-cell selection (147). Using a collec-
tion of agonist ovalbumin (OVA) peptide variants with graded
affinities toward the TCR on transgenic OT-I T lymphocytes these
investigators observed a distinct compartmentalization of Ras and
its downstream effector protein c-Raf (also known as Raf-1) in
dependency of agonist strength: in T-cells driven into negative
selection by high-affinity antigen peptides Ras and c-Raf distrib-
uted largely to the PM whilst positive selecting, low affinity ligands
induced a relocation of Ras and Raf to endomembranes. Intrigu-
ingly, localization of RasGRP1 followed a similar pattern. At first
sight the relocation of Ras signaling to endomembranes by high-
affinity ligands in the thymocyte selection model and by low-grade
TCR stimulation of Jurkat cells in the study by Perez de Castro
et al. (173) may appear hard to reconcile, although it is prob-
ably tedious to compare peptide/APC-stimulation of immature
double-positive thymocytes with Jurkat cells or primary mature T
cells challenged by means of cross-linking Abs. It is also important
to note that Ras accumulation at endomembranes, as observed
in positively selected thymocytes, must not necessarily reflect high
Ras·GTP loading and Ras signaling at that organelle. In this regard,
the coincident accumulation of Raf in the Golgi apparatus of pos-
itively selected thymocytes may not be a reliable marker for the
presence of Ras·GTP as suggested (147). Since only about 3%
of c-Raf interacts with Ras·GTP in antigen challenged T-cells at
the peak of Ras·GTP formation (226), the observed quantitative
relocation of c-Raf to endomembranes is unlikely to result from
recruitment by Ras·GTP but could rather argue for the action of
a small second messenger molecule in recruiting c-Raf. For exam-
ple, c-Raf is recruited and activated by PA (227, 228), and thus PA
generated by DGK-catalyzed phosphorylation of DAG or by PLD
activation downstream of PKC (229, 230) is an attractive can-
didate in this respect. In sum, the documentation of spatial Ras
segregation in the context of thymic selection provides important
evidence for a role of compartmentalized Ras signaling in T-cell
biology, but we need to understand more about the underlying
mechanisms governing spatial control of Ras activity. Moreover,
the fact that mice devoid of both palmitoylated Ras variants,
H-Ras and N-Ras, live a mostly healthy life (231), have normal
T-cell differentiation and feature only relatively minor defects in
mature lymphocyte biology (232) evidences that the compart-
mentalization of Ras signaling to endomembranes is not essential
or critically important for TCR-dependent signaling, at least in
rodents. Perhaps the ability to compartmentalize Ras signals to
endomembranes is part of a signaling repertoire for fine-tuning
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of TCR responses, the physiological relevance of which has so far
escaped our attention.
SOS1 AS A LIPID REGULATED ADAPTER MOLECULE
Overshadowed by its primary role as a RasGEF in the canonical
SOS-Ras pathways, it is relatively underappreciated that SOS1 may
function as a scaffold molecule that can potentially sense mem-
brane lipid- and protein-originated signals. Particularly interest-
ing is SOS’s PR C-terminal segment with multiple potential SH3
binding sites (PxxP motifs) and at least four sites that bind to
Grb2’s SH3 domain in vitro (32, 233). The multiplicity of the SH3
ligand sites in the C-terminus bestows the capacity to interact with
more than one interacting partner at any one time. The availability
for multiple PxxP motifs opens the possibility for interacting with
more than one molecule of Grb2 or other related SOS-interacting
SH3-SH2-SH3 adapters such as Grap or Gads. Thus, SOS may
function as a scaffold to integrate upstream membrane signals
and coordinate activation of multiple downstream pathways.
Houtman and colleagues actually observed complexes of SOS1
and Grb2 in a 1:2 stoichiometry, particularly when molar con-
centration of Grb2 is in excess (234). The multivalent interaction
between Grb2 and SOS can lead to formation of oligomeric LAT
clusters, in this case, SOS-Grb2 complex functions as a cytoso-
lic adapter cross-linking multiple LAT molecules together (234–
236) (Figure 7). Expression of PR C-terminal SOS1 fragment in
Jurkat cells decreases the size of aggregated LAT clusters and also
attenuates weak TCR stimuli-induced calcium flux (234). These
observations support the functional existence of SOS-Grb2-LAT
clusters, which can facilitate amplification of weak TCR stimula-
tion. SOS can also synergize with LAT clusters by stabilizing LAT
signalosome components such as PLCγ1. Upon TCR stimulation,
PLCγ1-SH2 is recruited and bound to tyrosine-phosphorylated
(Y132; human or Y136; mouse) LAT (237, 238). In addition, the
SH3 domain of PLCγ1 directly interacts with PR segments of
SOS both in vitro and in vivo, including in T lymphocytes (35–
38). Direct SOS-PLCγ1 binding can promote stable association of
PLCγ1 within LAT signalosome by collaborating with SH2-PLCγ1
binding with phospho-LAT. Additionally, direct SOS-PLCγ1 inter-
action can recruit PLCγ1 to the proximity of its substrate, PIP2,
which is also a ligand for the HF and PH domains of SOS as
described earlier. Thus, it is plausible that LAT and SOS together
nucleate a signaling hub in lymphocytes in which many molecules
and therefore pathways come together.
Our recent study indicates that SOS1 plays an important
adapter function regulating p38 pathway activation independently
of SOS1’ catalytic activity (92). In principle, SOS1’s DH domain
could act as nucleotide exchange domain in a SOS-Rac-P38 path-
way since DH domains are commonly shared structural modules
of GEFs regulating Rho family GTPases such as Rac (23, 239).
Indeed, SOS has been suggested to operate as a GEF with dual
specificity: REM-Cdc25 domains targeting for Ras and DH and
PH domain for Rac (240). The latter activity occurs in epithelial
cells when SOS1 is coupled to EPS8 and E3b1 co-factors (22, 23,
39). Rac·GTP accumulation is thought to be upstream of classi-
cal p38 activation pathway (241, 242). Interestingly, the absence
of SOS-1 and -2 profoundly impairs BCR-stimulated Rac·GTP
accumulation and p38 activation (92). Combined deficiency of
FIGURE 7 | An adapter function for SOS in oligomeric LAT clusters?
Grb2-SOS complexes can serve as a cytosolic linkers and aggregate
multiple LAT molecules and LAT signalosome-constituent proteins together.
This SOS-containing complex may facilitate activation of other,
non-canonical Ras-ERK signal transduction pathways such as activation of
the MAPK p38, perhaps through a Vav-Rac·GTP connection. We found that
regulation of p38 is independent of any enzymatic function of SOS, further
strengthening the notion that SOS can signal as an adapter to non-canonical
pathways in lymphocytes.
RasGRP-1 and -3 abolishes BCR-induced ERK activation, while its
impact on p38 phosphorylation (pT180pY182) is only minimal
(92). Unexpectedly, SOS1 versions with either a point mutation
(F929A) within Cdc25 that cripples SOS1’s RasGEF function, an
allosteric pocket mutation W729E, or a mutation of seven amino
acids in the DH domain (LHYFELL→ IIIRDII) that would dis-
rupt SOS1’s putative RacGEF activity, all rescue BCR-induced p38
phosphorylation in SOS-deficient DT40 B cells, indicating that
enzymatic activity of SOS1 is not required for p38 regulation and
SOS1 is functioning as an adapter for p38 activation pathway (92).
Thus, whereas the exact nature of SOS1’s adapter function and
the potential role of phospholipids binding to SOS1 as an adapter
(Figure 7) remain to be further studied, p38 appears to connect to
a non-canonical SOS pathway in lymphocytes.
CONCLUDING REMARKS
The need for controlled Ras activation in not only lymphocytes
but also in all other cell types is clearly provided by the devastating
consequences of aberrant, oncogenic Ras signals in cancer. Not
all cell types express both the SOS and RasGRP types of RasGEFs
and lymphocytes are perhaps somewhat unique in that these cells
have developed an intricate mechanism for sensitive and robust
Ras signals via both types of RasGEFs that is still under tight
control. We have discussed how membrane recruitment and bio-
chemical activation of the RasGRP and SOS RasGEF is fine-tuned
through the concerted input of various mechanisms that include
lipid messengers. Future research will undoubtedly further refine
the model of Ras activation we sketched here and may reveal how
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lipid messengers could integrate signals to RasGRP and SOS as
adapters in non-canonical pathways that are distinct from Ras.
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